Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery  by Amar, David et al.
tal stay with accompanying increased costs, as well as
greater need for hospital readmission after discharge.
The risk of stroke is greater in patients with postopera-
tive AF.1,2,4 The etiologic mechanisms of this complica-
tion are poorly understood. As in AF unrelated to oper-
ations, age of 60 years or older is consistently the only
independent preoperative risk factor most strongly
associated with postoperative AF.1-5 Biochemical stud-
ies done in our laboratory have shown a persistent
downregulation and desensitization of the lymphocyte
β-adrenergic receptor/adenyl cyclase system that corre-
sponded to global reductions in measures of heart rate
variability throughout the first postoperative week.6
These and other data7,8 support the presence of
increased sympathetic activity, parasympathetic with-
drawal, or both during this critical period. We hypothe-
sized that postoperative AF may be mediated, in part, by
calcium channel mechanisms in response to adrenergic
hyperactivity. Recent investigations in animals9 and
human subjects10-12 showed that L-type calcium channel
Of the 600,000 Americans who undergo major car-diothoracic operations annually, more than 150,000
will have postoperative atrial arrhythmias, of which
atrial flutter/fibrillation (AF) is the most common.1-3
Patients with postoperative AF have an extended hospi-
Objectives: We sought to determine whether early prophylaxis with an L-
type calcium channel blocker reduces the incidence and morbidity associat-
ed with atrial fibrillation/flutter and supraventricular tachyarrhythmia after
major thoracic operations.
Methods: In this randomized, double-blind, placebo-controlled study, 330
patients were given either intravenous diltiazem (n = 167) or placebo (n =
163) immediately after lobectomy (≥60 years) or pneumonectomy (≥18
years) and orally thereafter for 14 days. The primary end point with respect
to efficacy was a sustained (≥15 minutes) or clinically significant atrial
arrhythmia during treatment.
Results: Postoperative atrial arrhythmias (atrial fibrillation/flutter = 60;
supraventricular tachyarrhythmias = 5) occurred in 25 (15%) of the 167
patients in the diltiazem group and 40 (25%) of the 163 patients in the place-
bo group (P = .03). When compared with placebo, diltiazem nearly halved
the incidence of clinically significant arrhythmias (17/167 [10%] vs 31/163
[19%], P = .02). The 2 groups did not differ in the incidence of other major
postoperative complications or overall duration or costs of hospitalization.
No serious adverse effects caused by diltiazem were seen.
Conclusions: After major thoracic operations, prophylactic diltiazem reduced
the incidence of clinically significant atrial arrhythmias in patients consid-
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blockers possess antiarrhythmic capability against AF.
Favorable pilot data from our institution established
that diltiazem is well tolerated after thoracotomy.13
Thus, this study was designed to determine whether
early L-type calcium channel blockade with diltiazem
reduces the incidence and morbidity of postoperative
atrial arrhythmia.
Methods
Patient population. This study was approved by the
Institutional Review Board of Memorial Sloan-Kettering
Cancer Center, and written informed consent was obtained
from each patient before the operation. To be eligible,
patients had to be in sinus rhythm and at increased risk for
postoperative arrhythmias either because they were sched-
uled to undergo a pneumonectomy or were over 60 years of
age and scheduled to have a lobectomy. Patients were
excluded if they had a history of chronic atrial arrhythmia
or second-degree atrioventricular block or were taking
class I or class III antiarrhythmic drugs or calcium-channel
blockers for ischemic heart disease. Patients who had new
signs of myocardial ischemia or infarction or required
inotropic support on arrival to the postanesthesia care unit
were also excluded. Preoperative medications were contin-
ued until the time of the operation. Patients taking L-type
calcium-channel blockers for hypertension (n = 8) received
other antihypertensive medications postoperatively, as clin-
ically indicated. β-Blockers were continued postoperative-
ly to avoid withdrawal.
A total of 503 patients with pulmonary or pleural malignant
tumors were enrolled from February 1997 to August 1999.
Patients who were found to have unresectable disease at the
time of operation because of extensive spread of tumor (n =
32) or those who underwent a lesser operation (n = 135) were
excluded from the study. Four patients were excluded from
the study after randomization but before the study medication
was given: two patients had acute myocardial ischemia or
infarction during or immediately after the operations; one
patient had persistent hypotension (systolic blood pressure <
80 mm Hg) requiring vasopressor therapy for greater than 12
hours; and one patient had a persistent sinus bradycardia
(heart rate < 50 beats/min). In addition, two patients were
wrongly enrolled into the study: one patient was being treat-
ed with a class III antiarrhythmic drug for paroxysmal AF,
and the other had poorly controlled hyperthyroidism and
paroxysmal AF. These 6 patients were not included in the
intention-to-treat analysis. The 330 consecutive patients who
underwent lobectomy (n = 232), pneumonectomy (n = 63), or
extrapleural pneumonectomy (n = 35) were randomly allo-
cated in a double-blind fashion in the immediate postopera-
tive period to receive diltiazem or placebo (see below). 
Study end points. The primary end point of the study was
the new onset of sustained (≥15 minutes) or clinically sig-
nificant (requiring intervention) AF or supraventricular
tachyarrhythmia (SVT) during the first 14 days after the
operation. AF was defined by an irregular cardiac rhythm,
other than sinus rhythm, confirmed by either ambulatory
electrocardiography (ECG) or 12-lead ECG. SVT was
defined as the new onset of paroxysmal supraventricular
tachycardia or multifocal atrial tachycardia necessitating
treatment. Once the primary end point was reached, the
assignment code was unblinded, and the primary physician
was allowed to cross over to diltiazem from placebo or
administer additional diltiazem or other medications as clin-
ically indicated. Patients in whom the heartbeat failed to
convert to sinus rhythm within 24 to 48 hours of AF onset
were given heparin followed by warfarin. The incidence of
late (>14 days) AF was recorded during hospitalization or if
documented as outpatients within 30 days of operation.
Need for intensive care unit (ICU) admission for any reason
during the 14-day treatment period was also recorded. Data
on total hospitalization costs for the study population were
provided through the use of a commercially available deci-
sion-support information software system (Financial
Management System; Shared Medical Systems, Malvern,
Pa) used by the patient account office at our institution.
Professional service fees were not included in these
charges. The 3M APR-DRG (All Patient Refined-
Diagnostic Related Groups; 3M Health Information
Systems, Salt Lake City, Utah) severity adjustment model
was used in adjusting for age, sex, comorbidity, operation,
and the interactions thereof. These adjustments were based
on the 1996 northeast normative data file. A relative
resource weight was established for each patient. These
weights were summed for each group and divided by the
total patients in the group, yielding a group case mix index.
The average cost per group was then divided by the case
mix index to develop a neutral cost per case. This neutral-
ized cost was then multiplied by the case mix index for all
patients analyzed (2.78) to yield an adjusted average cost.
Anesthesia, operation, and postoperative care. All
patients were premedicated with midazolam and glycopyrro-
late (INN: glycopyrronium bromide) and received standard
anesthetic management that consisted of isoflurane and
nitrous oxide supplemented by intravenous fentanyl and mor-
phine as needed. Intentional crystalloid restriction (<25
mL/kg) during the operation was attempted in all patients.
The operations were performed by experienced thoracic sur-
geons using standard thoracotomy approaches. Entry into the
pericardial space or resection of the pericardium was record-
ed. Resection was carried out in a manner designed to com-
pletely remove all neoplastic disease along with an ipsilater-
al mediastinal lymph node dissection. Intraoperative
estimated blood loss was recorded. Postoperative pain relief
was provided to all patients by continuous administration of
either epidural opioid (usually fentanyl) administration (n =
195) or intravenous opioid (usually morphine) patient-con-
trolled analgesia (n = 135). After an overnight stay in the
postanesthesia care unit, patients were transferred to the tho-
racic surgical floor on the first postoperative day.
Postoperative complications were recorded throughout the
hospital stay. A research nurse monitored patients for com-
plications as outpatients for 30 days and queried patients
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about intercurrent hospitalizations or emergency department
visits. An investigator reviewed these medical records. 
Ambulatory ECG. Continuous dual-lead ECG recordings
(leads CM2 and CM1 or CM5) were made on Marquette 8500
Holter recorders for 72 to 96 hours after the operation. QRS
complex recognition and arrhythmia detection were done
automatically by template matching. The decisions made
automatically by the computer were reviewed and corrected
by an experienced technician and then by a cardiologist.
Antiarrhythmic prophylaxis. Patients were randomly
assigned to receive either diltiazem or placebo with stratifi-
cation on the basis of the type of operation (ie, lobectomy,
pneumonectomy, or extrapleural pneumonectomy). Ran-
domization of patients in permuted blocks was done between
the epidemiology and biostatistics departments and the hos-
pital pharmacy with sealed, opaque, treatment-code
envelopes. All clinical and study personnel were blinded to
the study group assignments throughout the trial. On admis-
sion to the postanesthesia care unit, treated patients (n = 167)
received an intravenous loading dose of diltiazem (0.25
mg/kg [50 mL]) given over 30 minutes, followed by 0.1 mg ·
kg–1 · h–1 (constituted as 1 mg/mL) intravenously for 18 to 24
hours. Diltiazem was temporarily discontinued for systolic
hypotension (<80 mm Hg) or marked bradycardia (<50
beats/min). Similarly, control patients (n = 163) received
intravenous placebo loading doses of 50 mL given over 30
minutes, followed by a placebo infusion at 0.1 mL · kg–1 · h–1
given over the first 18 to 24 hours. Starting in the morning of
postoperative day 1, patients received either diltiazem SR 120
mg or placebo orally twice daily for a total of 14 days.
Patients who could not take oral medication during the treat-
ment period were temporarily switched to the intravenous
route. Adjustments in the oral dose were made for patients
weighing less than 50 kg, those who had a systolic blood
pressure of less than 90 mm Hg, or those showing other
adverse effects to diltiazem. Venous blood was drawn to
determine plasma diltiazem and magnesium levels on the
morning of postoperative day 3 before receiving the morning
dose. Plasma diltiazem concentration was determined by
high-performance liquid chromatography with ultraviolet
detection by Bioassay Laboratory (Houston, Tex).
Statistical analysis. We estimated that the overall inci-
dence of postoperative AF in this group would be 15%.3 To
detect an absolute reduction of 10% in the incidence of early
AF with a 2-tailed test at an α level of 5% with 80% power,
a sample size of 330 patients (165 per arm) would be
required. The sample size was adjusted for one interim analy-
sis with monitoring boundaries in the spirit of the O’Brien-
Fleming rule but with early rejection of either the null or the
alternative hypothesis.14 An interim analysis was performed
after 189 patients were enrolled. Atrial arrhythmias occurred
in 21 (22%) of 95 control subjects and 15 (16%) of 94 treat-
ed patients (P = not significant). The overall incidence of AF
with or without SVT was tested among all 3 subgroups
(lobectomy, pneumonectomy, and extrapleural pneumonecto-
my) with the Mantel-Haenszel test for differences in propor-
tions. All analyses were performed on an intention-to-treat
basis, and all P values are 2-tailed. Statistical analysis was
performed with the software SAS version 6.12 (SAS
Institute, Inc, Cary, NC). To determine the difference of
patient and operative characteristics between the 2 treatment
groups, we examined all variables by univariate analysis
(Student t test and Fisher exact test). Data are presented as
mean value ± SD unless otherwise indicated.
Results
Study population and surgical data. The 2 groups
were well matched in age, sex distribution, severity of
tumor stage, comorbidity, and surgical data (Table I).
Plasma magnesium concentrations taken on postopera-
tive day 3 were nearly identical in diltiazem-treated
patients (1.57 ± 0.17 mEq/L) versus control subjects
(1.56 ± 0.16 mEq/L, P = not significant; normal range,
1.4-2.2 mEq/L). Heart rate was identical in the dilti-
azem and placebo groups at baseline before the opera-
tion (77 ± 13 beats/min). However, during the first 72
hours after the operation, mean heart rate was greater
by 6 to 7 beats/min in the placebo group when com-
pared with that found in the diltiazem-treated patients
(P < .01). The 2 groups did not differ in the incidence
of nonsustained ventricular or supraventricular ectopy,
as determined by Holter monitoring.
Postoperative atrial arrhythmias. A total of 65
patients had sustained atrial arrhythmias detected, as
determined by Holter criteria, clinical criteria, or both,
within the first 14 days of operation: AF (n = 60), parox-
ysmal supraventricular tachycardia (n = 3), and multifo-
cal atrial tachycardia (n = 2). Diltiazem significantly
reduced the overall (with or without symptoms) inci-
dence of postoperative atrial arrhythmias when com-
pared with placebo (25/167 [15%] vs 40/163 [25%],
P = .03) and nearly halved the incidence of clinically
significant atrial arrhythmias (17/167 [10%] vs 31/163
[19%], P = .023; Table II). Five of 46 patients with clin-
ically significant AF were initially noted to have asymp-
tomatic episodes of sustained AF, as determined by
Holter monitoring. AF occurred a mean of 2.7 ± 1.7
days (median, 2 days) after the operation in patients
assigned to diltiazem and 3.3 ± 2.5 days (median, 3
days) in patients assigned to placebo (P = .32). In 41 of
60 AF episodes, the average heart rate in the hour pre-
ceding AF could be determined and was found to be
similar between the diltiazem and placebo groups (91 ±
15 vs 92 ± 10 beats/min, P = .87). The maximal ven-
tricular rate during AF was significantly lower in the
diltiazem group than in the placebo group (145 ± 34 vs
163 ± 26 beats/min, P = .02). There was no significant
difference between the groups in the duration of AF
(diltiazem: 21.8 ± 38.1 hours vs placebo: 16.2 ± 21.9
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hours, P = .52; Table III). Late AF (>14 days) occurred
in 2 diltiazem-treated patients on postoperative days 17
and 20 and in 1 patient from the placebo group on post-
operative day 18. One of these episodes was associated
with acute pulmonary embolism and 1 with pneumonia.
AF or SVT episodes that did not respond to diltiazem
therapy were initially managed by a class III antiar-
rhythmic drug in 2 patients assigned to placebo and 1
patient assigned to diltiazem. β-Blockers were given to
4 patients assigned to placebo and 2 patients in the dil-
tiazem group. Five patients in each group were given
digoxin. No patient required electrical cardioversion.
Once the ventricular response was controlled, no
patient had evidence of myocardial ischemia or infarc-
tion. Nine (15%) of 60 patients with AF required anti-
coagulation on discharge from the hospital, of whom 4
were originally assigned to the diltiazem group. Two of
these 9 patients who were originally assigned to place-
bo remained in AF 2 months after their operations.
Length of hospital stay and total costs. Length of
hospital stay did not differ between patients assigned to
diltiazem in comparison with control subjects (8.9 ±
7.9 vs 8.7 ± 7.8 days, P = .82). The median length of
hospital stay was 7 days for both groups. The mean
total hospitalization costs for the diltiazem group were
$23,773 ± $19,443 compared with $23,515 ± $18,152
for the placebo group (P = .90). Patients with a clini-
cally significant arrhythmia (n = 48) had a longer
length of hospital stay (14.4 ± 13.0 vs 7.9 ± 6.1 days,
P = .001) when compared with patients who did not
have an arrhythmia (n = 282) and were more frequent-
ly 60 years or older (47/290 vs 1/40, P = .02). Mean
hospitalization costs for patients who had a clinically
significant arrhythmia were $26,013 ± $21,636 versus
$23,070 ± $16,730 in those patients who did not 
(P = .28). There was a trend for patients who had clin-
ically significant arrhythmias and received diltiazem 
(n = 17) to have lower hospitalization costs than simi-
lar control subjects (n = 31; $22,498 ± $15,378 vs
$28,508 ± $26,144, P = .16). Nonbillable services
associated with every symptomatic arrhythmia includ-
ed more intense nursing coverage, additional monitor-
ing, and more frequent house staff visits.
Subgroup analyses. Diltiazem therapy reduced the
incidence of early postoperative AF in patients under-
going lobectomy when compared with placebo (16/117
vs 29/115, P = .03), as well as in patients 60 years or
older (all 3 subgroups; P = .05; Table II). In the dilti-
azem group the incidence of AF was 24% (4/17
patients) among the patients receiving β-blockers and
13% (20/150 patients) among those not receiving β-
blockers. In the placebo group the incidence of AF was
Table I.  Patient characteristics
Characteristic Diltiazem (n = 167) Placebo (n = 163) P value
Age (y) 66 ± 10 67 ± 10 .7  
Male sex, n (%) 91 (54) 86 (53) .83
Weight (kg) 74 ± 15 74 ± 16 .94
Smoking, n (%) 132 (79) 132 (81) .68
Diabetes mellitus, n (%) 15 (9) 12 (7) .69
Coronary artery disease, n (%) 8 (5) 13 (8) .27
Hypertension, n (%) 49 (29) 52 (32) .63
Preoperative medications 
β-Blockers, n (%) 17 (10) 17 (10) .99
Calcium-channel blockers, n (%) 7 (4) 1 (1) .07
Digoxin, n (%) 2 (1) 3 (2) .89
β-Agonist inhalers, n (%) 16 (10) 16 (10) .99
Preoperative chemotherapy, n (%) 41 (25) 34 (21) .43
Operation type .99
Lobectomy, n (%) 117 (70) 115 (71)
Pneumonectomy, n (%) 32 (19) 31 (19)
Extrapleural pneumonectomy, n (%) 18 (11) 17 (10)
Right thoracotomy, n (%) 94 (56) 80 (49)
Intraoperative data
Estimated blood loss (L) 0.5 ± 0.7 0.4 ± 0.5 .31
Pericardiotomy, n (%) 30 (18) 33 (20) .68
Tumor stage .99
I + II, n (%) 95 (57) 97 (60)
III + IV, n (%) 52 (31) 53 (33)
Not staged, n (%) 20 (12) 13 (8)
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also 24% (4/17 patients) among the patients receiving
β-blockers and 22% (32/146 patients) among those not
receiving β-blockers. The use of β-blockers did not
influence the incidence of AF in either study group 
(P = .40, Fisher exact test).
When all patients were combined, those in whom AF
developed were found to be older than those in whom
AF did not develop (71 ± 7 vs 66 ± 10 years, P < .01).
Patients with AF had a longer length of hospital stay
(12.9 ± 12.1 vs 7.9 ± 6.2 days, P = .002). More patients
with AF had ICU admission (9/60) compared with
patients without AF (6/270, P < .01). The use of 
β-blockers did not differentiate patients who did or did
not have AF (8/60 [13%] vs 26/270 [10%], P = .36).
Side of operation and presence of pericardiotomy did
not differentiate patients in whom AF did or did not
develop (data not shown).
Morbidity and mortality in the hospital. There was
no significant difference in the incidence of postoperative
complications between the two groups (Table IV).
Among patients who had a clinically significant arrhyth-
mia, other major postoperative complications occurred in
4 (24%) of 17 patients assigned to diltiazem and in 8
(26%) of 31 assigned to placebo (P = .99). One patient
who was treated with diltiazem had a cerebrovascular
accident attributed to new-onset AF within 24 hours of its
onset. In this patient the first 12 hours of AF were asymp-
tomatic. The length of stay in the ICU did not differ
between patients assigned to diltiazem (8.0 ± 4.7 days, n
= 7) compared with patients assigned to placebo (8.4 ±
4.8 days, n = 8; P = .88). The reasons for ICU admission
were pneumonia (n = 8), acute respiratory distress syn-
drome (n = 3), AF (n = 2), and pulmonary embolism (n =
2). Death within 30 days of the operation occurred in 3
patients assigned to placebo and in 1 patient assigned to
diltiazem (P = .37, Table IV).
Compliance with treatment and adverse effects.
Six patients receiving diltiazem and 1 receiving
placebo required a transient interruption in therapy
because of mild hypotension in the postoperative
anesthesia care unit (P = .12). Two diltiazem-treated
patients had an interruption of intravenous drug ther-
apy for more than 12 hours because of a borderline
systolic blood pressure but continued with their oral
therapy. In no patient was there a precipitous drop in
blood pressure seen with any dose of diltiazem. The
oral dose of diltiazem was decreased in 2 patients
whose sitting systolic blood pressure was 90 to 100
mm Hg before discharge from the hospital. Seven
patients refused to continue on the study within the
first 48 hours, and 2 patients elected to drop out after
7 days of treatment. Side effects potentially related to
diltiazem included dyspepsia (1 patient) and rash (1
patient). The mean plasma diltiazem level deter-
mined on the morning of postoperative day 3 was 310
± 164 ng/mL (range, 26-742 ng/mL; median, 283
ng/mL) and was within the reported therapeutic
range (79-294 ng/mL).15 In a subset of 17 of 24
patients in whom AF developed during diltiazem
treatment, the plasma diltiazem levels did not differ
from levels found in those without AF (n = 121; 294
± 150 vs 312 ± 167 ng/mL, P = .67).
Table II. Incidence of atrial arrhythmias
Diltiazem Placebo
No. % No. % P value
All atrial arrhythmias 25/167 14 40/163 26 .03
AF 24/167 14 36/163 22 .07
Lobectomy 16/117 14 29/115 25 .03
Pneumonectomy 7/32 22 3/31 10 .32
Extrapleural pneumonectomy 1/18 6 4/17 24 .18
Patients ≥ 60 y
All atrial arrhythmias 24/149 16 38/141 27 .03
Clinically significant arrhythmias 17/149 11 30/141 21 .03
AF 23/149 15 35/141 25 .05
Clinically significant AF 16/149 11 28/141 20 .03
Table III.  Duration of AF*
Duration Diltiazem (n = 24) Placebo (n = 36)
<8 h 11 18
8-24 h 9 11
>24 h 4 7
Values are in numbers of patients.
*There was no significant difference in the duration of AF between the 2
groups (P = .88, Fisher exact test).
reducing the duration of postoperative therapy to 10
days because the majority of arrhythmias occurred
before this time in our study.
Previous studies. Our early experience with the pro-
phylactic use of diltiazem after pneumonectomy
showed an overall reduction of AF or SVT by 50%
when compared with that of patients treated with
digoxin or with a comparison control group.13 The
sample size of that study was relatively small, and this
difference only approached significance. The use of
verapamil by other investigators immediately after tho-
racic operations for 72 hours was associated with sim-
ilar reductions in the AF rate but with greater side
effects related to a large loading dose.17 In another
study of patients undergoing coronary artery bypass
grafting (CABG), short-term diltiazem therapy that
was started during cardiopulmonary bypass and contin-
ued for 24 hours was shown to significantly reduce the
AF incidence from 18% to 5%.18 The limitations of
that study, however, were the lack of arrhythmia defin-
ition and monitoring reported for only 24 hours. β-
Blockers have also been used for many years to prevent
AF after cardiothoracic operations, but their efficacy
for this purpose has been marginal.1,2,19-21
In contrast to rate-control drugs, more recent reports
have investigated the use of the class III antiarrhyth-
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 4
Amar et al 795
Discussion
Main findings. The use of prophylactic diltiazem
starting immediately after thoracic operations and con-
tinuing for 2 weeks was well tolerated and reduced the
incidence of clinically significant atrial arrhythmias by
approximately 45%. When compared with placebo, dil-
tiazem reduced the average heart rate early after the
operation, as well as the ventricular response rates dur-
ing acute AF or SVT. Diltiazem reduced the rate of AF
occurrence significantly in the lobectomy subgroup but
not in the pneumonectomy groups. In our experi-
ence,3,13 the observed incidence of AF was lower than
expected in patients undergoing pneumonectomy who
were assigned to placebo. This is likely a result of the
sample size and relatively younger age of patients
undergoing pneumonectomy compared with that of the
lobectomy subgroup.
Diltiazem therapy did not alter the overall length of
hospital stay despite reducing the number of clinically
significant episodes of AF and SVT. This may be due
to the relatively early onset of AF when compared with
the median length of hospital stay of 1 week in both
groups and our practice of discharging patients after
early anticoagulation. AF has recently been shown to
be the single most important cause for hospital read-
mission after fast-track cardiac operations.16 Unlike
patients undergoing cardiac operations who are fast-
tracked, it is possible that our patients’ postoperative
comorbidities, such as pneumonia or a prolonged air
leak, masked the effect of diltiazem on the overall
length of hospital stay. The significantly higher length
of hospital stay in our patients with an arrhythmia is
consistent with findings in other studies.1-4 The burden
of AF after cardiac operations on hospital costs is well
documented.1,2,4 In our study the mean hospitalization
cost attributed to a clinically significant arrhythmia
was close to $3000. Our results demonstrated that a
14-day course of intravenous and oral diltiazem ($120
hospital cost, n = 167) was responsible for a 45% (14
patients) risk reduction of clinically significant atrial
arrhythmias. Assuming that these 14 patients were to
have an arrhythmia and that their total costs would
exceed that of patients without an arrhythmia by
$3000, this would translate into cost savings after the
cost of diltiazem is deducted. Because extended moni-
toring, intensity of nursing care, and house staff inter-
ventions were not billed for at our institution, our cost
savings with diltiazem are probably underestimated.
Strategies that can further maximize the cost effective-
ness of diltiazem could include beginning oral therapy
before the operation, shortening the course of intra-
venous diltiazem therapy after the operation, and
Table IV.  Postoperative major morbidity and 
mortality
Variable Diltiazem (n = 167) Placebo (n = 163)
Major morbidity
Pneumonia 7 8
Prolonged air leak 9 7
Paralytic ileus 3 1
Pulmonary embolism 3 1
Acute respiratory failure 1 2
Acute renal failure 0 2
Wound infection 0 2
Cerebrovascular accident 1 0
Total* 24 (14%) 23 (14%) 
Hospital readmission within 





Total* 6 (3.6%) 4 (2.5%)
Mortality within 30 d 
of operation
Acute respiratory distress 1 2
syndrome
Sudden death 0 1
Total* 1 (0.6%) 3 (2%)
*P = not significant, diltiazem versus placebo.
mics amiodarone and ibutilide in patients undergoing
cardiac operations.22-24 The first report involved a rela-
tively small group of patients given amiodarone for 1
week before CABG, valvular operation, or both and
showed a significant effect of therapy on the incidence
of AF (25% vs 53%), on hospital stay, and on cost when
compared with placebo.22 In a larger trial limited to
patients undergoing CABG, amiodarone prophylaxis
reduced the AF incidence from 47% to 35% but had no
effect on hospital stay or cost.23 Despite these reported
reductions in AF rates with amiodarone,22,23 the overall
incidence of AF remained high, and when coupled with
its significant cost and the potential for side effects, its
routine use for prophylaxis against postoperative AF
has been discouraged.25 The concern of lung injury
associated with amiodarone therapy in a small study of
patients undergoing thoracic operations requires further
confirmation.26 Ibutilide has been shown to be effective
in the conversion of acute AF after cardiac operations
but was associated with a 1.8% risk of polymorphic
ventricular tachycardia.24 As in AF unrelated to an
operation, it is not clear whether antiarrhythmics are
superior to rate-control drugs in the management of
postoperative AF.25 In fact, a recent preliminary study
of postoperative AF reported that the strategy of rhythm
control is not superior to that of rate control for attain-
ment of any clinical end point.27
Limitations of the study. First, on the basis of our
prior work,3,13 we expected that younger age would not
affect the incidence of AF after pneumonectomy. By
study design, patients undergoing pneumonectomy
were younger than patients undergoing lobectomy. We
believe that this, combined with the smaller sample size
in the pneumonectomy groups and the lower than
expected AF occurrence, limited our ability to find a
meaningful comparison between diltiazem-treated and
control patients. Second, Holter recordings were made
during the first 72 to 96 hours after the operation, a
period when most arrhythmias are known to occur. Our
conclusions beyond this monitoring period are limited
to clinically evident episodes of AF. Third, our practice
setting precluded doing a more exact cost analysis to
assess the true burden of AF.
Potential mechanisms. Postoperative atrial arrhyth-
mias and AF specifically may be seen in 2% to 4% of
elderly patients undergoing noncardiothoracic opera-
tions.28,29 The clinical presentation is identical whether
a patient has had cardiac, thoracic, or other types of
operations. What differs is the greater incidence of AF
after cardiothoracic operations.28 Although the etiolog-
ic mechanisms of postoperative AF are poorly under-
stood, it has been shown that AF is generally initiated
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by an ectopic beat.30 Whether the ectopic beat triggers
AF depends on the vulnerability of the atrium. Atrial
vulnerability is determined by a complex interaction of
factors: dispersion of refractoriness, electrical remodel-
ing, wavelength of the re-entrant impulse (product of
the refractory period by the conduction velocity), and
autonomic balance.31 To date the only consistent clini-
cal predictor of postoperative AF is older age.1-5 It is
widely known that aging causes degenerative changes
in atrial anatomy32,33 that are accompanied by shorter
atrial effective refractoriness, longer sinoatrial and
atrioventricular nodal conduction times, atrial stiffen-
ing, and splitting of the atrial excitation waveform
caused by the pectinated trabeculae.34 Experimental
studies have shown that sympathetic stimulation by
itself will not produce AF, whereas regional sympa-
thetic denervation indirectly changed the vagal effects
on atrial refractoriness to facilitate sustained AF.34,35
We speculate that cardiac and thoracic operations pro-
vide a model of regionally denervated atria as a result
of varying degrees of unavoidable trauma to sympatho-
vagal fibers originating from the deep and superficial
cardiac plexi to the atria.13 Whether there is a yet unde-
fined atrial denervation supersensitivity phenomenon
to circulating plasma catecholamines in response to
cardiothoracic operations is unknown, but this has been
contemplated to explain atrial arrhythmias in a totally
denervated transplanted heart.36
The higher incidence of AF and other re-entry type
atrial arrhythmias in the control group confirms the data
from laboratory9 and clinical studies10-12 suggesting that
intracellular calcium-lowering drugs mitigate some of
the atrial electrophysiologic mechanisms that predispose
to AF onset. The likely multifactorial composition of the
substrate for postoperative AF partially explains why
more than 60% of patients do not have this complication
after cardiothoracic operations.28 It also explains why
clinical studies examining one mechanism, such as pro-
longed intra-atrial conduction (prolonged signal-aver-
aged P-wave duration) as a predictor of postoperative
AF, have provided conflicting results.37-39
Conclusions
Postoperative AF is a frequent and serious complica-
tion in elderly patients undergoing thoracic operations.
It is commonly associated with hemodynamic compro-
mise, greater need for ICU stay, increased hospital stay
and readmission, and, less frequently, with stroke.
Prophylactic diltiazem in this study was safe and near-
ly halved the incidence of clinically significant AF,
SVT, or both, in patients known to be at increased risk
for this complication. To the best of our knowledge,
12. De Simone A, Stabile G, Franco D, Turco P, DiStasio M,
Petrazzuoli F, et al. Pretreatment with verapamil in patients with
persistent or chronic atrial fibrillation who underwent electrical
cardioversion. J Am Coll Cardiol 1999;34:810-4.
13. Amar D, Roistacher N, Burt M, Rusch VW, Bains MS, Leung
DHY, et al. Effects of diltiazem versus digoxin on dysrhythmias
and cardiac function after pneumonectomy. Ann Thorac Surg
1997;63:1374-82.
14. Pampallona S, Tsiatis AA. Group sequential designs for one-
sided and two-sided hypothesis testing with provision for early
stopping in favor of the null hypothesis. J Stat Plan Inference
1994;42:19-35
15. Dias VC, Weir SJ, Ellenbogen KA. Pharmacokinetics and phar-
macodynamics of intravenous diltiazem in patients with atrial
fibrillation or atrial flutter. Circulation 1992;86:1421-8.
16. Lahey SJ, Compos CT, Jennings B, Pawlow P, Stokes T, Levitsky
S. Hospital readmission after cardiac surgery: Does “fast track”
cardiac surgery result in cost saving or cost shifting? Circulation
1998;98(Suppl):II-35-40.
17. Van Mieghem W, Tits G, Demuynck K, Lacquet L, Deneffe G,
Tjandra-Maga T, et al. Verapamil as prophylactic treatment for
atrial fibrillation after lung operations. Ann Thorac Surg
1996;61:1083-6.
18. Seitelberger R, Hannes W, Gleichauf M, Keilich M, Christoph M,
Fasol R. Effects of diltiazem on perioperative ischemia, arrhyth-
mias, and myocardial function in patients undergoing elective
coronary bypass grafting. J Thorac Cardiovasc Surg
1994;107:811-21.
19. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of
supraventricular arrhythmias after coronary artery bypass
surgery: a meta-analysis of randomized controlled trials.
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cardia early after coronary artery revascularization: a randomized
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this is the first large, randomized, controlled trial to
demonstrate that calcium-channel blockers clearly pre-
vent the occurrence of AF after major thoracic opera-
tions. On the basis of these results, we consider it
appropriate to use diltiazem prophylaxis as standard
care in patients over the age of 60 years undergoing
major pulmonary resection.
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